1-5 of 5
Joanne Wilson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases

Alessia Anastasia, Giulia Dellavedova, Antonio Ramos-Montoya, Neil James, Giovanna Chiorino, Massimo Russo, Hana Baakza, Joanne Wilson, Carmen Ghilardi, Elaine B. Cadogan, Raffaella Giavazzi, Maria Rosa Bani
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (4): 555–567.
https://doi.org/10.1158/1535-7163.MCT-21-0420
Published: 01 April 2022
View articletitled, The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
Open the PDF for The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases in another window
Includes: Supplementary data
Journal Articles

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Vikki Flemington, Emma J. Davies, David Robinson, Linda C. Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D. Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E. Willis, Martine P. Roudier, Claire Rooney, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Stephen E. Fawell, Clifford D. Jones, Richard A. Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease, Paul D. Smith
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (2): 238–249.
https://doi.org/10.1158/1535-7163.MCT-20-0002
Published: 05 February 2021
View articletitled, AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
Open the PDF for AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib in another window
Includes: Supplementary data
Journal Articles

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed F. Ahmad, Gareth Hughes, Victoria Sheridan, Rajesh Odedra, Paul Farrington, Elaine B. Cadogan, Lucy C. Riches, Antonio Garcia-Trinidad, Andrew G. Thomason, Bhavika Patel, Jennifer Vincent, Alan Lau, Kurt G. Pike, Thomas A. Hunt, Amrita Sule, Nicholas C.K. Valerie, Laura Biddlestone-Thorpe, Jenna Kahn, Jason M. Beckta, Nitai Mukhopadhyay, Bernard Barlaam, Sebastien L. Degorce, Jason Kettle, Nicola Colclough, Joanne Wilson, Aaron Smith, Ian P. Barrett, Li Zheng, Tianwei Zhang, Yingchun Wang, Kan Chen, Martin Pass, Stephen T. Durant, Kristoffer Valerie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1637–1647.
https://doi.org/10.1158/1535-7163.MCT-17-0975
Published: 31 July 2018
View articletitled, Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice
Open the PDF for Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice in another window
Includes: Multimedia, Supplementary data
Journal Articles

Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547

Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret Veldman-Jones, Joanne Wilson, Barry R. Davies, Jonathan R. Dry, Elaine Kilgour, Paul D. Smith
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2802–2813.
https://doi.org/10.1158/1535-7163.MCT-16-0297
Published: 01 November 2016
View articletitled, Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547
Open the PDF for Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 in another window
Includes: Supplementary data
Journal Articles

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Sarah A. Loddick, Sarah J. Ross, Andrew G. Thomason, David M. Robinson, Graeme E. Walker, Tom P.J. Dunkley, Sandra R. Brave, Nicola Broadbent, Natalie C. Stratton, Dawn Trueman, Elizabeth Mouchet, Fadhel S. Shaheen, Vivien N. Jacobs, Marie Cumberbatch, Joanne Wilson, Rhys D.O. Jones, Robert H. Bradbury, Alfred Rabow, Luke Gaughan, Chris Womack, Simon T. Barry, Craig N. Robson, Susan E. Critchlow, Stephen R. Wedge, A. Nigel Brooks
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (9): 1715–1727.
https://doi.org/10.1158/1535-7163.MCT-12-1174
Published: 05 September 2013
View articletitled, AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Open the PDF for AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo in another window
Includes: Supplementary data